DDDD.L Share News (DDDD)

UK Shareholder Meetings Calendar - Next 7 Days

Tuesday 15 MayAmerisur ResourcesMacfarlane GroupSpirax-Sarco EngineeringAnglo Pacific

4D Pharma Sets Up Phase Two Study For Bowel Syndrome Treatment Blautix

LONDON (Alliance News) - Biotherapeutics developer 4D Pharma PLC said on Tuesday that the US Food & Drug Administration has cleared the Investigational New Drug Application for irritable bowel

4D Pharma Loss In 2017 Widens On Higher Research And Development Costs

LONDON (Alliance News) - Drug development firm 4D Pharma PLC said Monday its loss widened in 2017 on higher research and development costs as it continued to progress its pipeline and clinical in

4D Pharma To Shortly Begin Clinical Studies On MRx0518 Treatment

LONDON (Alliance News) - 4D Pharma PLC on Wednesday said it is close to starting clinical studies on its potential MRx0518 cancer treatment.MRx0518 is a single strain a

4D Pharma Reports Encouraging Results From Blautix Phase 1 Trial

4D Pharma Loss Narrows As Operating And Research Costs Fall

4D Pharma begins Thetanix phase 1 clinical trial

(ShareCast News) - Pharmaceutical company 4D pharma has begun dosing in a phase 1 clinical trial with Thetanix for the treatment of Paediatric Crohn's disease (PCD). PCD is a rare chronic inflammatory bowel disease that is caused by the malfunction of the immune system leading to inflammation, or sw

4D Pharma announces encouraging first clinical trial of Blautix

(ShareCast News) - 4D Pharma announced a positive response from its Blautix treatment for irritable bowel syndrome (IBS) in a phase 1 clinical trial. The trial was a first in man study and, as previously reported by the company, Blautix was found to be both safe and well tolerated and achieved the p

4D Pharma Says Positive First Trial Of Product Blautix "Encouraging"

4D Pharma Gets Approval To Restart Thetanix Phase I Clinical Study

4D Pharma irritable bowel treatment proves safe in clinical trial

(ShareCast News) - Early clinical trials of 4D Pharma's treatment for irritable bowel syndrome (IBS) have successfully shown Blautix to be safe and well tolerated. Blautix, which contains live bacteria, like all 4D's products, was delivered orally to 56 healthy volunteers and IBS patients. Data fro

4d Pharma Says Blautix Treatment Meets Primary Endpoint In Trial

AGM, EGM Calendar - Week Ahead

AGM, EGM Calendar - Week Ahead

4D Pharma gobbles up Biomar production assets

(ShareCast News) - 4D Pharma announced a major acquisition on Friday, gobbling up the production assets of Spanish-based contract research organisation Biomar. The AIM-traded pharmaceutical company, which focuses on the development of live biotherapeutics, said Biomar had been working as an outsourc